Boceprevir

The PBAC noted that the only update to the economic model in this minor submission from the March 2012 submission was a reduction in price. The price reduction resulted in revised base case ICERs at a 50 year time horizon of $15,000- $45,000 per QALY for treatment naive patients and $15,000- $45,000 per QALY for treatment experienced patients (both reduced though in the same range from the March 2012 submission) The PBAC considered that the uncertainties with the economic model identified in March 2012 remained and therefore the resulting cost effectiveness of boceprevir/PR was uncertain. PBAC · 2012

Populationpatients 18 years or older who have compensated liver disease and who have received no prior interferon alfa or peginterferon alfa treatment for hepatitis C

Risk sharingThe PBAC recommended that the sponsors of boceprevir and telaprevir rebate to the Government 100 % of the cost of telaprevir and boceprevir above the estimates accepted by the PBAC.

The PBAC acknowledged and noted consumer comments on the boceprevir submission, though specific details of the consumer input were not elaborated in the document.

The PBAC acknowledged and noted the consumer comments on this item. Consumer comments · PSD

Label narrower than PBS population — PBAC restricts to treatment-naïve patients (no prior interferon), compensated liver disease, age ≥18, and specific combination therapy requirement.